Press release, Helsinki, 13 January 2021 at 13.00 New Study Presents Impressive Results of Nexstim SmartFocus® nTMS Language Mapping Nexstim Plc announces that a new study published in. | January 14, 2021
Nexstim Oyj: New Study Presents Impressive Results of Nexstim SmartFocus nTMS Language Mapping
New Study Presents Impressive Results of Nexstim SmartFocus nTMS Language Mapping
Nexstim Plc (NXTMH:HEX, NXTMS:STO) ( Nexstim or Company ) announces that a new study published in
Cancers in January presents impressive results of nTMS language mapping in a large amount of patients. Using the robustness of Nexstim SmartFocus nTMS data, the authors also introduce a new and more precise classification of what it means to be a language eloquent tumour, challenging the traditional methods that seek to only identify hemispheric dominance for language.
The study Non-Invasive Mapping for Effective Preoperative Guidance to Approach Highly Language-Eloquent Gliomas-A Large Scale Comparative Cohort Study Using a New Classification for Language Eloquence , using Nexstim s NBS System with SmartFocus nTMS, was published by a neurosurgical team at Technical University of Munich (TUM) in Germany.
Nexstim Oyj: Nexstim Has Received Three New NBS System Orders
Nexstim Has Received Three New NBS System Orders
Nexstim Plc (NXTMH:HEX, NXTMS:STO) ( Nexstim or Company ) announces that it has received three new NBS system orders in December.
One purchase order came from a new neurosurgical customer in Spain. Two other orders came from existing Nexstim system users in Finland and in the United States. Those two orders are for NBS System upgrades meaning that an NBS System with the latest SmartFocus nTMS features will replace the hospital s older NBS system.
Nexstim NBS systems with SmartFocus nTMS are mainly used for neurosurgical diagnostics to provide information on tumour s or on other lesion s location in relation to the essential functions and their connections in the patient s brain. In addition, NBS Systems are used in research and in Europe the systems can also be used for depression and chronic, neuropathic pain therapy.
Share:
Nexstim Has Received Three New NBS System Orders
Nexstim Plc (NXTMH:HEX, NXTMS:STO) ( Nexstim or Company ) announces that it has received three new NBS system orders in December.
One purchase order came from a new neurosurgical customer in Spain. Two other orders came from existing Nexstim system users in Finland and in the United States. Those two orders are for NBS System upgrades meaning that an NBS System with the latest SmartFocus® nTMS features will replace the hospital s older NBS system.
Nexstim NBS systems with SmartFocus® nTMS are mainly used for neurosurgical diagnostics to provide information on tumour s or on other lesion s location in relation to the essential functions and their connections in the patient s brain. In addition, NBS Systems are used in research and in Europe the systems can also be used for depression and chronic, neuropathic pain therapy.
Nexstim Oyj: Nexstim Plc Annuls Stock Options Held by the Company
Nexstim Plc Annuls Stock Options Held by the Company
Nexstim Plc (NXTMH:HEX, NXTMS:STO) ( Nexstim or Company ) announces that its Board of Directors has resolved in its meeting on 15.12.2020 on annulment of in total 3,108 option rights 2016B; in total 65,827 option rights 2016C; in total 33,888 option rights 2018A; and in total 33,888 option rights 2018B which are in the possession of the Company or have been returned to the possession of the Company due to ended employments.
Pursuant to the annulment, no option rights in those plans remain in the possession of the Company. The Board of Directors of the Company also resolved on annulment of all option rights in the stock option plan 2017 which have been returned to the possession of the Company due to an ended employment and resolved on termination of the stock option plan 2017.